

Clinical Trials of Parkinson's Disease Drug Therapies with Primary Completion Date within 6 months of 31-Dec-2022

trial data: ClinicalTrials.gov

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Primary Completion Date	Completion Date
NCT02897063	Droxidopa	Loma Linda University/Lundbeck	Norepinephrine prodrug	Phase 1	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	34	1-Mar-2023	1-Aug-2023
NCT03413384	Ceftriaxone	Brainix	Ceftriaxone	Phase 2	To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	106	30-Jun-2023	31-Dec-2023
NCT03652870	Nortriptyline/Escitalopram	University College London	Antidepressants	Phase 3	Antidepressants Trial in Parkinson's Disease	408	31-Jan-2023	30-Apr-2023
NCT03655236	K0706/SCC - 138	Sun Pharma/SPARC	Bcr/Abl kinase inhibitor	Phase 2	PROSEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706	504	1-Mar-2023	1-Mar-2023
NCT03775096	Carvedilol	Cedars Sinai	Adrenergic blocker	Phase 2	Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)	15	1-May-2023	1-May-2023
NCT03947216	Pimavanserin	Strasbourg University Hospital	Inverse agonist/antagonist of 5HT2a receptors	Phase 2	Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-Hydroxytryptamine 2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.	130	31-May-2023	31-Jul-2023
NCT04075318	UB-312	Vaxxinity (was United Neuroscience)	"Endobody" to aSN	Phase 1	Study of UB-312 in Healthy Participants and Parkinson's Disease Patients	70	22-Feb-2023	22-Feb-2023
NCT04154072	NLY-01 (pegylated exenatide)	Neuraly/Johns Hopkins	GLP-1 agonist	Phase 2	A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease	255	1-Mar-2023	1-Mar-2023
NCT04251585	Nasal insulin	HealthPartners Institute	Intra-nasal insulin	Phase 2	Intranasal Insulin in Parkinson's Disease	30	1-Jun-2023	1-Jul-2023

NCT04334317	TAK-071	Takeda	M1 positive allosteric modulator	Phase 2	A Study of TAK-071 in People With Parkinson Disease	64	10-Feb-2023	10-Feb-2023
NCT04542499	Tavapadon (PF-06649751)	Cerevel	Dopamine D1/5 partial agonist	Phase 3	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	368	1-Feb-2023	1-Mar-2023
NCT04643327	Levetiracetam	Queensland University	Anti-epileptic	Phase 2	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	28	1-Jun-2023	1-Dec-2023
NCT04802733	MSK-DA01	Memorial Sloan Kettering Cancer Center	Human ESC-derived neural precursor cells	Phase 1	Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease	12	1-May-2023	1-May-2024
NCT04831281	ATH-1017	Athira Pharma	Enhances Hepatocyte Growth Factor activity	Phase 2	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	28	1-Apr-2023	1-May-2023
NCT04978597	Opicapone	Neurocrine	Catechol-O methyltransferase (COMT) inhibitor	Phase 3	Early Parkinson with L-DOPA/DDCI and Opicapone (EPSILON Study)	324	1-May-2023	1-May-2023
NCT05104463	CST-103 and CST-107	CuraSen Therapeutics	Restores brain homeostasis	Phase 2	A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease	60	1-Jun-2023	1-Dec-2023
NCT05297201	CPL500036	Celon Pharma	PDE 10A inhibitor	Phase 2	Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia	108	1-Feb-2023	1-Mar-2023
NCT05492019	Doxycycline	Bangabandhu Sheikh Mujib Medical University	Tetracycline class antibiotic	Phase 2	Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients	60	1-Jan-2023	1-Jan-2023
NCT05523570	HNC364	Guangzhou Henovcom Bioscience Co. Ltd.	Long-acting (monthly) injectable MAO-B inhibitor	Phase 1	A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension	18	7-Feb-2023	5-Apr-2023
NCT05603715	Pyridostigmine	University of Vermont	Cholinesterase inhibitor	Phase 2	Pyridostigmine for the Treatment of Constipation in Parkinson Disease	16	1-Feb-2023	1-Dec-2023